Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against ...

Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), currently trading at $0.58 with a market capitalization of $33.37 million, disclosed the results of its annual meeting of stockholders held on May ...

May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...

Rani Therapeutics Holdings, Inc. has announced a research agreement with Chugai Pharmaceutical Co., Ltd. to evaluate the potential of Rani’s oral delivery technology, specifically the RaniPill ...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS ...

Rani Therapeutics announced positive preclinical data for RT-114 and semaglutide, advancing toward Phase 1 obesity trials in mid-2025. Rani Therapeutics Holdings, Inc. has announced preclinical ...

Rani Therapeutics shares are trading lower by 23% Tuesday afternoon. The company announced a $10 million direct offering of 3 million shares at $3 per share. Get stock picks, daily rankings ...

Rani Therapeutics (NASDAQ:RANI) is developing a robotic pill to allow oral delivery of otherwise injectable medications. RANI has provided sufficient proof-of-concept data, both in animal models ...

Short interest in Rani Therapeutics Holdings Inc (NASDAQ:RANI) increased during the last reporting period, rising from 2.34M to 2.40M. This put 11.9% of the company's publicly available shares short.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), currently trading at $0.58 with a market capitalization of $33.37 million, disclosed the results of its annual meeting of stockholders held on May 28, ...

Please go ahead. Thank you, Operator. Please turn to Slide 2. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; and Chief Financial Officer, Svai Sanford.